Clinical Trial Detail

NCT ID NCT01109069
Title Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

B-cell lymphoma

Therapies

Ibrutinib

Age Groups: adult senior

No variant requirements are available.